![heroes 2.0 level conversion heroes 2.0 level conversion](https://images-sea.dragonnest.com/cms-sea/2/20190308/2019030815291618072.png)
Participants self-collected a midturbinate nasal swab weekly, regardless of COVID-19–associated illness symptom status and collected an additional nasal swab and saliva specimen at the onset of COVID-19–associated illness. Active surveillance for symptoms consistent with COVID-19–associated illness (defined as fever, chills, cough, shortness of breath, sore throat, diarrhea, muscle aches, or loss of smell or taste) occurred through weekly text messages, e-mails, and direct participant or medical record reports. The current vaccine effectiveness analytic study period began on the first day of vaccine administration at study sites (December 14–18, 2020) and ended March 13, 2021. HEROES-RECOVER ¶ is a network of longitudinal cohorts in eight locations (Phoenix, Tucson, and other areas in Arizona Miami, Florida Duluth, Minnesota Portland, Oregon Temple, Texas and Salt Lake City, Utah) that share a common protocol and methods.** Enrollment in this longitudinal study started in July 2020 and included health care personnel, first responders, and other essential and frontline workers who provided written consent. COVID-19 vaccination is recommended for all eligible persons. These findings indicate that authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection, regardless of symptom status, among working-age adults in real-world conditions.
#HEROES 2.0 LEVEL CONVERSION FULL#
Estimated mRNA vaccine effectiveness for prevention of infection, adjusted for study site, was 90% for full immunization and 80% for partial immunization. § In contrast, among fully immunized (≥14 days after second dose) persons, 0.04 infections per 1,000 person-days were reported, and among partially immunized (≥14 days after first dose and before second dose) persons, 0.19 infections per 1,000 person-days were reported. † Among unvaccinated participants, 1.38 SARS-CoV-2 infections were confirmed by reverse transcription–polymerase chain reaction (RT-PCR) per 1,000 person-days. Among 3,950 participants with no previous laboratory documentation of SARS-CoV-2 infection, 2,479 (62.8%) received both recommended mRNA doses and 477 (12.1%) received only one dose of mRNA vaccine. locations during December 14, 2020–March 13, 2021, CDC routinely tested for SARS-CoV-2 infections every week regardless of symptom status and at the onset of symptoms consistent with COVID-19–associated illness.
![heroes 2.0 level conversion heroes 2.0 level conversion](https://i.redd.it/9zgwkgnrkuv61.jpg)
Using prospective cohorts of health care personnel, first responders, and other essential and frontline workers* in eight U.S. Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic COVID-19 in randomized placebo-controlled Phase III trials ( 1, 2) however, the benefits of these vaccines for preventing asymptomatic and symptomatic SARS-CoV-2 (the virus that causes COVID-19) infection, particularly when administered in real-world conditions, is less well understood. Fry, MD 1 Manjusha Gaglani, MBBS 9 ,11 ( View author affiliations) View suggested citation Arvay, PhD 1 Preeta Kutty, MD 1 Alicia M.
![heroes 2.0 level conversion heroes 2.0 level conversion](https://i.imgur.com/tBa6a0j.png)
Morrill, MS 7 Josephine Mak, MPH 1 Patrick Rivers, MPP 2 Katherine M. Herring, MPH 7 Gregory Joseph, MPH 1 Shawn Beitel, MSc 2 Tyler C. Wesley, MPH 7 Julie Mayo Lamberte, MSPH 1 Xiaoxiao Sun, PhD 2 Michael E. Edwards, MPH 7 Natasha Schaefer-Solle, PhD 8 Lauren Grant, MS 1 Katherine Ellingson, PhD 2 Holly C. Hegmann, MD 5 Elisha Stefanski 6 Laura J. Kuntz, PhD 3 Kayan Dunnigan, MPH 9 Marilyn J. Caban-Martinez, DO 8 Ashley Fowlkes, ScD 1 Karen Lutrick, PhD 2 Jennifer L.
![heroes 2.0 level conversion heroes 2.0 level conversion](https://i.redd.it/6oh4xr0j9rc51.jpg)
Yoon, DO 5 Jennifer Meece, PhD 6 Lauren E.W.